Both at the real business condition and on the valuation cycle on the street. The Indian pharmaceutical sector has undergone significant changes over the past decade. Marking a transition from a period of consolidation and valuation readjustment to one where the focus has shifted towards more sustainable and compliant operational practices. This transformation highlights a shift in the strategic approach adopted by pharmaceutical companies. Historically, the expansion strategies of many pharma companies were driven by optimistic powerpoint presentations forecasting market growth. However, this approach often overlooked the critical aspect of regulatory compliance, leading to various challenges. Over the years the Indian pharmaceutical industry has understood that regulatory compliance might be slightly more time consuming and also expensive but in long run it pays both for the real business growth and improving valuations. Will the industry remember the critical lesson is key.
